Partnering on cardiovascular health

Researchers from the Baker Department of Cardiovascular Research, Translation and Implementation at La Trobe University are working with the Australian Cardiovascular Alliance to increase the visibility of cardiovascular disease as a national health priority area

Researchers from the Baker Department of Cardiovascular Research, Translation and Implementation at La Trobe University are working with the Australian Cardiovascular Alliance (ACvA) to increase the visibility of cardiovascular disease as a national health priority area.

One in four Australians die of cardiovascular disease. At around $11.8 billion annually, cardiovascular disease is the nation’s highest disease expenditure.

Researchers from the Baker Department of Cardiovascular Research, Translation and Implementation at La Trobe University are working with the Australian Cardiovascular Alliance (ACvA) to increase the visibility of cardiovascular disease as a national health priority area.

Established in 2015, the ACvA is the peak leadership body in the country for the advancement of heart, stroke and vascular disease research.

Comprising cardiovascular and stroke researchers, scientific societies, industry and non-government organisations andmedical research institutes, the ACvA works to harness the power of the whole cardiovascular research ecosystem to tackle the most urgent clinical challenges in cardiovascular health.

The ACvA advocates for strategies, policy change and investments to ensure that innovative approaches to diagnosis and care are efficiently translated to the patient, to improve outcomes for patients and reduce costs.

The ACvA has established seven strategic flagships to lead this agenda including Drug Discovery and Translation, Implementation and Policy, Big Data, Clinical Trials and Biomedical Engineering and most recently the Disease Mechanisms Flagship. These Flagships bring together key capabilities across the whole research pipeline.

Professor Peter Meikle, Head of the Baker Department, is Co-Director of the Precision Medicine Flagship.

“Our goal is to identify the best evidence-based prevention and treatment programs for patients,” explains Professor Meikle.

The Flagship is working on screening, diagnostic and monitoring strategies to provide targeted and tailored prevention and treatment of cardiovascular disease.

“We are also establishing an Australian Cardiovascular disease Data Commons (ACDC) that will facilitate data sharing from over 70,000 individuals with genomic and lipidomic data, linked to clinical outcomes,” says Professor Meikle.

“The ACDC platform will provide a unique resource and facilitate the development of precision medicine approaches to risk assessment and management of cardiovascular disease.”

The ACVA flagships are bringing together researchers, clinicians, industry, and policy makers to transform our approach to cardiovascular health and improve outcomes for all Australians.

Find out more about the Australian Cardiovascular Alliance.

Find out more about the Baker Department of Cardiovascular Research, Translation and Implementation on the website, Facebook and LinkedIn.